CO5180629A1 - Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas - Google Patents
Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasasInfo
- Publication number
- CO5180629A1 CO5180629A1 CO00058849A CO00058849A CO5180629A1 CO 5180629 A1 CO5180629 A1 CO 5180629A1 CO 00058849 A CO00058849 A CO 00058849A CO 00058849 A CO00058849 A CO 00058849A CO 5180629 A1 CO5180629 A1 CO 5180629A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- andgt
- amino
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula<EMI FILE="00058849_1" ID="1" IMF=JPEG >En la que R1 es hidrógeno, perfluoroalquilo C1-C4, alquilo C1-C8 o cicloalquilo C3-C8, pudiendo contener dichos alquilo C1-C8 o cicloalquilo C3-C8, opcionalmente de uno a tres heteroátomos seleccionados independientemente de oxígeno, ANDgt;NR5 y azufre; pudiendo estar también dichos alquilo C1-C8 cicloalquilo C3-C8 opcionalmente sustituidos por uno o dos sustituyentes seleccionados independientemente de alquilo C1-C4, arilo C6-C10, heteroarilo C2-C10, OH, NH2, (alquil C1-C4)amino, di[alquil C1-C4]amino, (cicloalquil C3-C8)amino, (cicloalquil C3-C8)(alquil C1-C4)amino, alcoxi C1-C4, -CONH2, -CONHR4, -CON(R4)2 y cicloalquilo C3-C8, pudiendo contener dicho cicloalquilo C3-C8 opcionalmente uno o dos heteroátomos seleccionados independientemente de ANDgt;NR5, oxígeno o azufre. R2 y R3 se seleccionan independientemente de hidrógeno o alquilo C1-C4, pudiendo contener dicho alquilo C1-C4 opcionalmente un heteroátomo seleccionado de oxígeno,ANDgt;NR5 oazufre y pudiendo estar dicho alquilo C1-C4 opcionalmente sustituido por arilo C6-C10, heteroarilo C2-C10, OH, NH2, (alquil C1-C4)amino, di[(alquil C1-C4)]amino, (cicloalquil C3-C8)amino, (cicloalquil C3-C8)(alquil C1-C4)amino, alcoxi C1-C4, -CON(R4)2 o cicloalquilo C3-C8, pudiendo contener dicho cicloalquilo C3-C8 uno o dos heteroátomos seleccionados independientemente de ANDgt;NR5, oxígeno o azufre;X se selecciona del grupo formado por oxígeno, azufre, ANDgt;SO2, ANDgt;S=O, ANDgt;NR4, -CH2O-, -OCH2-, -CH2S-, -CH2(S=O)-, -CH2SO2-, -SCH2-, -SOCH2-, -SO2CH2-, -N(R4)CH2-, -CH2N(R4)-, -N(R4)SO2- y -SO2N(R4)-;R4, siempre que esté presente, se selecciona independientemente de hidrógeno y alquilo C1-C4;R5, siempre que esté presente, se selecciona independientemente de hidrógeno, alquilo C1-C4, arilo C6-C10, heteroarilo C2-C10, OH, -CONH2, -CONHR4, -CON(R4)2 y cicloalquilo C3-C8;Y se selecciona del grupo formado por un enlace, oxígeno, azufre, ANDgt;SO2, ANDgt;S=O, ANDgt;NH, -CH2-, -CH2O-, -OCH2-, -CH2S-, -CH2(S=O)-, -CH2SO2-, -SCH2-, -SOCH2-, -SO2CH2, -NHCH2-, -CH2NH-, -CH2CH2-, -CH=CH-, -NHSO2- y -SO2NH-;Ar1 es arilo C6-C10 o heteroarilo C2-C10; y- 2 -Z es arilo C6-C10, cicloalquilo C3-C8 (cicloalquil C3-C8) (alquilo C1-C4) o heteroarilo C2-C10; pudiendo estar uno o dos de los átomos de carbono del anillo de dichos cicloalquilo C3-C8 o (cicloalquilC3-C8)( alquilo C1-C4) opcionalmente reemplazados por heteroátomos seleccionados independientemente de oxígeno, azufre y NR5;pudiendo estar Ar1 y Z opcionalmente sustituidos en cualquiera de los átomos de carbono del anillo que puedanformar un enlace adicional por uno a tres sustituyentes seleccionados independientemente de F, Cl, Br, CN, OH, alquilo C1-C4, perfluoroalquilo C1-C4, perfluoroalquiloxi C1-C4, alquiloxi C1-C4 y cicloalquiloxi C3-C8);o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14854799P | 1999-08-12 | 1999-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5180629A1 true CO5180629A1 (es) | 2002-07-30 |
Family
ID=22526231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00058849A CO5180629A1 (es) | 1999-08-12 | 2000-08-04 | Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US6579982B1 (es) |
| EP (1) | EP1202974B1 (es) |
| JP (1) | JP2003507371A (es) |
| KR (2) | KR20020047119A (es) |
| CN (1) | CN1156454C (es) |
| AR (1) | AR025091A1 (es) |
| AT (1) | ATE309224T1 (es) |
| AU (1) | AU773751B2 (es) |
| BG (1) | BG106406A (es) |
| BR (1) | BR0013081A (es) |
| CA (1) | CA2381551A1 (es) |
| CO (1) | CO5180629A1 (es) |
| CR (1) | CR6565A (es) |
| CZ (1) | CZ2002355A3 (es) |
| DE (1) | DE60023903D1 (es) |
| EA (1) | EA004680B1 (es) |
| EC (1) | ECSP003610A (es) |
| EE (1) | EE200200069A (es) |
| GE (1) | GEP20053424B (es) |
| GT (1) | GT200000137A (es) |
| HK (1) | HK1045995B (es) |
| HN (1) | HN2000000137A (es) |
| HR (1) | HRP20020129A2 (es) |
| HU (1) | HUP0202501A3 (es) |
| IL (1) | IL148035A0 (es) |
| IS (1) | IS6248A (es) |
| MA (1) | MA26812A1 (es) |
| MX (1) | MXPA02001561A (es) |
| NO (1) | NO20020662L (es) |
| NZ (1) | NZ516562A (es) |
| OA (1) | OA12000A (es) |
| PA (1) | PA8498701A1 (es) |
| PE (1) | PE20010491A1 (es) |
| PL (1) | PL353871A1 (es) |
| SK (1) | SK1652002A3 (es) |
| TN (1) | TNSN00169A1 (es) |
| TR (1) | TR200200381T2 (es) |
| UY (1) | UY26285A1 (es) |
| WO (1) | WO2001012611A1 (es) |
| YU (1) | YU6602A (es) |
| ZA (1) | ZA200201070B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| KR20040004412A (ko) * | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
| US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| PL362919A1 (en) * | 2000-10-26 | 2004-11-02 | Pfizer Products Inc. | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| EP1368323B1 (en) | 2001-02-14 | 2010-06-30 | Warner-Lambert Company LLC | Pyrimidine matrix metalloproteinase inhibitors |
| EP1368327B1 (en) | 2001-02-14 | 2004-10-20 | Warner-Lambert Company LLC | Benzo thiadiazine matrix metalloproteinase inhibitors |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6936620B2 (en) | 2001-12-20 | 2005-08-30 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US7101883B2 (en) | 2002-03-18 | 2006-09-05 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| JP2005529895A (ja) * | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | Ｎ置換へテロアリールオキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤 |
| ATE304015T1 (de) * | 2002-04-26 | 2005-09-15 | Pfizer Prod Inc | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren |
| MXPA04010550A (es) * | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona. |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| BR0313459A (pt) * | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014908A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| JP2006500351A (ja) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体 |
| AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| WO2004084903A1 (en) * | 2003-03-27 | 2004-10-07 | F. Hoffmann-La Roche Ag | Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis |
| WO2004084902A1 (en) * | 2003-03-28 | 2004-10-07 | F. Hoffmann-La Roche Ag | Use of a trioxopyrimidine for the treatment of chronic wounds |
| US8088737B2 (en) | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| WO2012014109A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US20150366275A1 (en) * | 2014-06-19 | 2015-12-24 | Gyula Cserfoi | Wearable Signaling Device |
| GB201705255D0 (en) | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264045A1 (en) * | 1996-08-28 | 1998-03-05 | Randall Stryker Matthews | Heterocyclic metalloprotease inhibitors |
| JP2002504916A (ja) * | 1997-06-21 | 2002-02-12 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体 |
-
2000
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 CA CA002381551A patent/CA2381551A1/en not_active Abandoned
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko active IP Right Grant
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/en active IP Right Grant
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 EP EP00946235A patent/EP1202974B1/en not_active Expired - Lifetime
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Application Discontinuation
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
-
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown
- 2002-10-17 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5180629A1 (es) | Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas | |
| CO5180626A1 (es) | Derivados de purina inhibidores de proteina quinasa syk | |
| CO5271690A1 (es) | Derivados de pirimidina | |
| CO5251464A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina | |
| CO5170518A1 (es) | Compuestos n-(benzocicloalquilo) derivados de amino aralifaticos | |
| CO5080782A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa | |
| ID29452A (id) | 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus | |
| CO5200785A1 (es) | Uso terapeutico de quinazolina | |
| MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| CO5251467A1 (es) | Derivados de piperazina | |
| CO6241190A2 (es) | Compuestos para inhibicion enzimatica | |
| AR045782A2 (es) | Derivados de piperidina que tienen actividad farmaceutica | |
| CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
| CO4820431A1 (es) | Compuestos calciliticos habiles para inhibir la actividad receptora de calcio, composisicon farmaceutica y metodo de utilizacion | |
| CO5261565A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina | |
| CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
| CO5261612A1 (es) | Inhibidores de girasa y usos de esta | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| CO5251410A1 (es) | Derivados de nitrilo como inhibidores de la captesina k | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| EE200200148A (et) | Kinasoliini derivaadid, nende valmistamise meetodning kasutamine | |
| CO5160347A1 (es) | Derivados de acido carbamico | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| CO5320599A1 (es) | Inhibidores no peptidilicos de la union a las celulas depen dientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| BR9916566A (pt) | Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |